Linezolid-induced pancytopenia
- PMID: 30054325
- PMCID: PMC6067138
- DOI: 10.1136/bcr-2018-225480
Linezolid-induced pancytopenia
Abstract
Linezolid is a bacteriostatic antibiotic of the Oxazolidinone class; it works by inhibiting the initiation of protein synthesis on bacterial ribosomes. Due to its excellent bioavailability after oral dosing, it has become an important tool in combating multi-drug-resistant bacteria including glycopeptide-resistant enterococci and methicillin-resistant Staphylococcus aureus Side effects are multiple and potentially serious. We report the case of an 87-year-old man who developed pancytopenia secondary to a 6-week course of linezolid. Withdrawal of the antibiotic was decided as the treatment and resolution of the pancytopenia was evident within 2 weeks. Clinicians should be aware of this side effect of linezolid therapy and that weekly full blood count monitoring is paramount.
Keywords: drug therapy related to surgery; safety; unwanted effects / adverse reactions.
© BMJ Publishing Group Limited 2018. No commercial re-use. See rights and permissions. Published by BMJ.
Conflict of interest statement
Competing interests: None declared.
References
-
- Zyvox 600 mg Film-Coated Tablets - Summary of Product Characteristics (SmPC) - (eMC) Medicines.org.uk. https://www.medicines.org.uk/emc/product/1688/smpc
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical